Crossmark

Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial

Crossref DOI link: https://doi.org/10.1016/S0140-6736(21)00213-0

Published Print: 2021-03

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Davies, Melanie

Færch, Louise

Jeppesen, Ole K

Pakseresht, Arash

Pedersen, Sue D

Perreault, Leigh

Rosenstock, Julio

Shimomura, Iichiro

Viljoen, Adie

Wadden, Thomas A

Lingvay, Ildiko
Funding

Funding for this research was provided by:

Novo Nordisk
License Information

Text and Data Mining valid from 2021-03-01

stm-asf valid from 2021-03-01

stm-asf valid from 2021-03-01

stm-asf valid from 2021-03-01

stm-asf valid from 2021-03-01

stm-asf valid from 2021-03-01
More Information

This article is maintained by: Elsevier

Article Title: Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial

Journal Title: The Lancet

CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/S0140-6736(21)00213-0

CrossRef DOI link to the associated document: https://doi.org/10.1016/S0140-6736(21)00377-9

Content Type: article

Copyright: © 2021 Elsevier Ltd. All rights reserved.

Document is current

Any future updates will be listed below